Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend?

Pfizer reported year-end diluted EPS of $1.36, below its $1.72 annual dividend, while noting billions of asset impairment charges have depressed reported results. Revenue fell about 2% year-over-year and the company sees adjusted 2026 EPS of $2.80–$3.00, suggesting adjusted coverage of the payout; the stock trades at a depressed valuation after a ~38% three-year decline (but was up ~6% over the past 12 months) and yields roughly 6.3%. Key risks include patent cliffs and recent impairments, while prior investments and acquisitions are cited as potential supports for future growth and dividend sustainability.

Analysis

Contrarian angles: consensus underweights the possibility that impairments are largely non-cash and that adjusted EPS $2.80–$3.00 yields a materially lower payout risk than headline GAAP EPS suggests; market may be over-discounting assets acquired in 2023–2025. Reaction may be overdone if management demonstrates stable FCF conversion >60% of adjusted EPS over two consecutive quarters — that would likely compress yield by 150–300bps and re-rate PFE up 15–30%. Monitor dividend coverage (adjusted EPS and FCF) and upcoming pipeline readouts as primary catalysts.

Key Decisions for Investors

• Establish a 1–3% portfolio long position in PFE using a buy-and-hold to collect the 6.3% yield but simultaneously purchase a 12–18 month 15% OTM put (cost target <1.5% of notional) and sell a 12–18 month 25% OTM call to create a cost-effective collar; reassess after Q2 earnings confirming adjusted EPS trajectory.
• Implement a relative-value pair: go long 1.0% JNJ (or MRK) and short 0.7% PFE for 6–12 months to rotate into higher-quality growth in pharma; trim if spread tightens by 50% or if PFE outperforms by >20%.
• If you prefer options-only, sell covered calls on existing PFE position (3–6 month calls 10–20% OTM) to boost yield, but cap exposure so total delta risk ≤3% of equity portfolio; close if dividend yield compresses below 4.5% or free cash flow falls under 60% of adjusted EPS for two consecutive quarters.
• Avoid buying unhedged long positions >5% exposure until management demonstrates consistent adjusted FCF coverage and no additional material impairments; trigger to increase exposure: two consecutive quarters of FCF ≥60%×adjusted EPS and maintained guidance.